Although direct targeting of H2AFY remains difficult, a histone deacetylase (HDAC) inhibitors, such as sodium phenylbutyrate (SPB), downregulated the expression of H2AFY mRNA in patients with Huntington’s disease (41). This evidence concerns the gene HDAC9 and Huntington disease.